Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Arrowhead Pharmaceuticals Inc ARWR.OQ reported a quarterly adjusted loss of $1.26​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.38. The mean expectation of fifteen analysts for the quarter was for a loss of $1.03 per share. Wall Street expected results to range from $-1.29 to -29 cents per share.

• Revenue was $27.77 million​; analysts expected $23.71 million.

• Arrowhead Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.26​.

• The company reported a quarterly loss of $175.24 million.

• Arrowhead Pharmaceuticals Inc shares had risen by 3.2% this quarter and lost 13.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 13% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $39.50, about 59.3% above its last closing price of $16.06

This summary was machine generated from LSEG data August 8 at 03:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)